Navigation Links
AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
Date:5/27/2009

% - and that's only if the patient takes the necessary medication correctly and regularly. In contrast, our vaccine approach aims at decreasing the cholesterol transfer from HDL to LDL, thus increasing the concentration of the beneficial HDL. This vaccine approach with its long-lasting effects should avoid patients having to take life-long, daily medication to a strict regimen."

The main item of the joint efforts of AFFiRiS and EMC is the vaccination against cholesteryl ester transfer protein (CETP). By transferring cholesteryl ester from HDLc to LDLc and VLDLc, this protein reduces "good" HDL and has a detrimental impact on the ratio of LDLc to HDLc. In the future, our vaccine will reduce the activity of this protein and shift the balance of HDLc and LDLc in the blood back in favour of HDLc.

Outlining the major benefit of the AFFITOME(R) technology, project manager Dr. Sylvia Brunner adds: "CETP is one of the body's own proteins. Trying to reduce its activity using a vaccine, we are faced with a formidable challenge. The body has many means of suppressing an immune response to its own proteins, or limiting the effectiveness of any such response. That's why previous attempts to develop a vaccine against CETP failed. However, as AFFiRiS has already demonstrated in its work on a vaccine for Alzheimer's disease, the AFFITOME(R) technology makes it possible to circumvent these mechanisms. We are now applying this principle to atherosclerosis."

CEO Dr. Walter Schmidt continues: "So far, we have announced the development of vaccines for three diseases - Alzheimer's, Parkinson's and now atherosclerosis. Currently, four other indications are also part of our development pipeline, all of them characterised by a very high number of patients but also by a lack of satisfactory treatments. As a result, these indications fit in well with our long-term strategy. Our strategy itself is beginning to pay back as demons
'/>"/>

SOURCE AFFiRiS AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
2. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
3. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
4. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
5. Old and new therapies combine to tackle atherosclerosis
6. Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate
7. ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine
8. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
9. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
10. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
11. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
(Date:7/30/2014)... Diego, CA (PRWEB) July 30, 2014 ... contract from the U.S. Environmental Protection Agency (EPA). ... expertise in developmental toxicity models, including tests designed ... neuron formation and the formation of connections between ... Inhibition of neurodifferentiation and synapse formation by environmental ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
(Date:7/29/2014)... of significant technological challenges in their quest to ... for the James Webb Space Telescope. , The ... scientist at NASA,s Goddard Space Flight Center in ... arrays that is, those activated by applying ... the current technology,s magnetically activated arrays. This advance ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... are quickly eliminated from the body. Scientists at the ... a kind of molecular balloon that swells and thus ... The TUM spin-off XL-protein GmbH has now started to ... People who suffer from hepatitis B are often treated ...
... WOBURN, Mass., Sept. 21 The Center for Business Intelligence ... the proceeds from their Alzheimer,s Drug Development Summit to the ... this week, September 21-25, 2009, in recognition of World Alzheimer,s ... Alzheimer,s associations, globally, to raise awareness and encourage citizens to ...
... NEW YORK, Sept. 21 Emissary Capital Group, ... (OTC Bulletin Board: SNBP) with a Buy rating and ... domestically as Dong Ying Pharmaceutical Co. Ltd., is a ... R&D, manufacture and distribution of biopharmaceutical products. The ...
Cached Biology Technology:Researchers prolong the plasma half-life of biopharmaceutical proteins 2Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association 2Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association 3Emissary Capital Group Initiates Coverage on Sinobiopharma 2
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... Steven Chown has been awarded the Scientific Committee ... in Antarctic Research. , SCAR, an inter-disciplinary international ... international scientific research in the Antarctic region, and ... the Earth system. The organisation also provides scientific ... responsible for governing the region. , The medal ...
(Date:7/30/2014)... in cancer treatment has been shown to relieve ... for neural transmission between the peripheral and central ... Institute of Radiation Medicine, Chinese Academy of Medical ... into rat dorsal root ganglia (DRG) to provide ... radioactivity (0, 14.8, 29.6 MBq) were implanted separately ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2
... Harnessing the strength of a natural process that ... from UT Southwestern Medical Center has helped establish ... and permanently correct mutations in disease-causing genes. , ... By artificially initiating a DNA repair process known ...
... Scientists studying mice have identified a gene that allows ... the inflammatory chemicals they secrete. , Researchers at Washington ... knocking the gene out in mice prevented the development ... of their own damaging secretions. , The newly identified ...
... by Professor Hans-Georg Kräusslich at Heidelberg University Hospitals, ... Tumor Virology of the Deutsches Krebsforschungszentrum (German Cancer ... label Human Immunodeficiency Viruses (HIV) for visual investigations ... , The labeling permits scientists to observe the ...
Cached Biology News:Researchers pioneer new gene therapy technique using natural repair process 2Researchers pioneer new gene therapy technique using natural repair process 3Disabling gene defuses rheumatoid arthritis in mice 2Disabling gene defuses rheumatoid arthritis in mice 3New Species of Coral Discovered Off Southern California 2
Request Info...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
... 96 Well BAC Prep; Ideal ... from 1.5ml 2xYT cultures; Provides ... fluorescent sequencing for small to ... strategy which minimizes shearing and ...
Biology Products: